Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT00722956 Completed - Healthy Volunteers Clinical Trials

Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin

Start date: July 2008
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the pharmacokinetics of both AZD5672 (steady-state) and atorvastatin (single dose) when co administered in healthy volunteers

NCT ID: NCT00720421 Completed - Healthy Volunteer Clinical Trials

A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine the effects of the compound AZD7325 as compared to lorazepam on sleepiness, concentration and brain activity.

NCT ID: NCT00719459 Completed - Healthy Volunteers Clinical Trials

Bioequivalency Study Comparing Hospira's Generic Iron Sucrose Injection to Venofer

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the bioequivalence of the test product Hospira Iron Sucrose 20 mg/mL (Hospira, Inc.) to the reference product Venofer® 20 mg/mL following intravenous administration to healthy subjects.

NCT ID: NCT00717912 Completed - Healthy Volunteers Clinical Trials

Determination of the Glycemic Index and the Insulinemic Index of a Sweetener Syrup

Start date: July 2008
Phase: N/A
Study type: Interventional

The purpose of the study is to determine the glycemic index and the insulinemic index of a sweetener syrup

NCT ID: NCT00716846 Completed - Healthy Volunteers Clinical Trials

Effects of Statins on the Pharmacokinetics for Midazolam in Healthy Volunteers

H-17-21
Start date: June 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate whether statins have any influence on cytochrome P450 (CYP) 3A4 enzyme activity using a probe drug midazolam.

NCT ID: NCT00713271 Completed - Healthy Volunteers Clinical Trials

Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men

AZD3199MAD
Start date: August 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety and tolerability of multiple once daily ascending doses of AZD3199 in healthy men

NCT ID: NCT00710047 Completed - Healthy Volunteers Clinical Trials

Food Effect Study of a Single Dose of ZD4054 (Zibotentan)

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the effect of food on the pharmacokinetics of a 10 mg single oral dose of ZD4054 (Zibotentan)

NCT ID: NCT00707538 Completed - Healthy Volunteers Clinical Trials

A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of this clinical research study is to learn the biodistribution of injection of BMS747158 at stress and assess the safety of two doses of BMS747158

NCT ID: NCT00706381 Completed - Healthy Volunteers Clinical Trials

Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs)

Start date: June 23, 2008
Phase: Phase 3
Study type: Interventional

Postprandial thermogenesis, or thermic effect of food are terms that describe the increase in utilization of energy by the human body following a meal. The mechanisms involved in this process are believed to differ according to the type of food consumed, whether fat, protein or carbohydrate. The bile acids (BAs), unique substances secreted by the gall bladder into the gut after a meal, play an important role in the absorption of fat and the management of cholesterol stores in the body. Recent studies suggest that BAs may also serve as regulators of energy expenditure (consumption) in the cells of our body by increasing the production of T3, an active form of thyroid hormone. T3 in turn is believed to increase the efficiency with which our bodies burn calories thereby generating heat. Although this process has been shown to be effective in rodents who demonstrated weight loss after treatment, the role of BAs in humans is poorly understood. Thus we do not know whether endogenous (produced by the body) or exogenous (taken as medication) BAs play a significant role in the maintenance of body weight. We hypothesize that, similarly to rodents, humans will respond to BAs by increasing energy expenditure via the production of the active form of thyroid hormone. This randomized, cross-over study will look at changes in thyroid hormones and energy consumption in response to stimuli of endogenous BA secretion including dietary content, and to the intake of pharmacological doses of bile acids. Following a two-day period of equilibration diet, 30 healthy volunteers will be randomly assigned to receive either a high-fat or high-carbohydrate isocaloric meal followed by a 6-hour metabolic chamber stay; the next day they will be crossed-over to the alternate intervention. During the following three days, the study subjects will again be randomized to receive either an intravenous injection of sincalide (the C-terminal octapeptide fragment of cholecystokinin) 0.04 mcg/kg or placebo and P.O. placebo, or I.V. placebo and 15 mg/kg of BA (ursodiol) with similar metabolic chamber stays and cross-over design. The data gathered from this study will provide greater insight into the physiological and molecular mechanism(s) regulating the relation between endogenous bile acid secretion and energy metabolism in response to meals, as well as the role of BAs per se on energy metabolism.

NCT ID: NCT00702676 Completed - Healthy Volunteers Clinical Trials

Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison

Start date: July 2008
Phase: Phase 1
Study type: Interventional

This study will compare the tolerability of Quetiapine Fumarate immediate release formulation and Quetiapine Fumarate extended release formulation during initial dose escalation in healthy volunteers.